ARGENX SE

ARGX
Real-time Quote. Real-time  - 12/02 05:30:38 am
258.9EUR +3.60%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Number of employees : 336 people.
Sales per Business
20192020
Upfront Payments22.3632%30.3583.3%
Research and Development19.3427.7%3.068.4%
Milestone Payments28.0940.2%3.028.3%
EUR in Million
Sales per region
2020
United States36.1399.2%
Denmark0.300.8%
Belgium--
EUR in Million
Managers
Name Title
Tim van Hauwermeiren Chief Executive Officer & Executive Director
Karl Gubitz Chief Financial Officer
Peter K. M. Verhaeghe Chairman
Hans J. W. de Haard Chief Scientific Officer
Wim Parys Chief Medical Officer
R. Keith Woods Chief Operating Officer
Joseph Donald DeBethizy Independent Non-Executive Director
Pamela M. Klein Independent Non-Executive Director
Anthony Adam Rosenberg Independent Non-Executive Director
Werner Lanthaler Non-Executive Director
Shareholders
Name Equities %
The Vanguard Group, Inc. 1,978,464 3.88%
Johnson & Johnson 1,766,899 3.47%
Wellington Management Co. LLP 1,545,652 3.03%
Federated Global Investment Management Corp. 1,522,200 2.99%
Baillie Gifford & Co. 1,401,085 2.75%
RTW Investments LP 1,346,136 2.64%
Norges Bank Investment Management 1,177,761 2.31%
Bellevue Asset Management AG 955,538 1.88%
BlackRock Fund Advisors 912,707 1.79%
Hans J. W. de Haard 495,975 0.97%
Company contact information
Willemstraat 5
NL-4811 AH Breda


Phone : +31 (0) 763 030 488
Fax :
web site : https://www.argenx.com/investors
Markets and indexes
- Compartiment A
- BEL 20 / Euronext 100, Next Biotech, PEA, STOXX Europe 600
Stock Exchange Codes
- Reuters Code :  ARGX.AS
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
ARGENX SE-3.56%14 579
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE310.30%84 953
WUXI APPTEC CO., LTD.30.33%66 734
REGENERON PHARMACEUTICALS31.76%66 553
VERTEX PHARMACEUTICALS-13.26%47 530
BEIGENE, LTD.34.50%32 613
GENMAB A/S3.05%25 290
ARGENX SE3.26%14 342
ACCELERON PHARMA INC.39.71%10 932
HUALAN BIOLOGICAL ENGINEERING INC.-32.50%8 284
NEUROCRINE BIOSCIENCES, INC.-13.15%7 898
ASCENDIS PHARMA A/S-15.09%7 772
MIRATI THERAPEUTICS, INC.-37.73%7 552
ARROWHEAD PHARMACEUTICALS, INC.-12.68%7 322
SAREPTA THERAPEUTICS, INC.-51.79%7 037
GW PHARMACEUTICALS PLC89.72%6 907
LEGEND BIOTECH CORPORATION82.92%6 851
REMEGEN CO., LTD.8.95%6 647
MARAVAI LIFESCIENCES HOLDINGS, INC.54.87%6 039
BIOCON LIMITED-22.56%5 706
Brand Portfolio
» More brands of Argenx SE